Precedent Transactions When There Are Four Comparables

Four precedent transactions can support a defensible value range for a clinical-stage life sciences company, but only after each deal is restated on a common basis. Across four public acquisitions announced between March 2024 and June 2025, the median premium to the unaffected share price is 102.5% on cash at closing, 120.6% with contingent value rights probability-weighted, and 214.4% if every milestone is assumed paid.

01The Comparable Set

Clinical-stage biopharma rarely has the earnings that anchor a precedent transactions analysis elsewhere. What remains is the price an acquirer paid for a pipeline, expressed per share and as a premium to the undisturbed market price. ASC 820 classifies this as the market approach, which uses prices generated by market transactions involving identical or comparable assets (ASC 820-10-55-3A), and it anticipates the problem of a small set: multiples may fall in a range, and selecting the point within it requires judgment (ASC 820-10-55-3B).

For a private company, the adjustments that turn a public deal into an input are unobservable. Level 3 inputs are unobservable inputs, developed using the best information available in the circumstances (ASC 820-10-35-52 and 35-54A), and a measurement is categorized in its entirety at the lowest level of any input significant to it (ASC 820-10-35-37 and 35-37A). The analysis is therefore Level 3, and its credibility rests on how transparently each adjustment is made.

Four comparables is a deliberate number. Stage, modality, indication and deal structure rarely align, and four closely comparable deals carry more information than twelve loosely matched ones. With four, the median is the average of the two middle observations and each deal carries a quarter of the mean, so one outlier shifts it materially. That argues for showing every adjustment.

02The Four-Comparable Method

03The Worked Example

The four transactions share a structure: a large strategic acquirer bought a publicly traded, single-lead-asset company for cash at closing plus one non-transferable CVR per share. They differ on stage, modality, indication and trigger, which the method is built to handle. The measurement date is August 28, 2025.

Terms are from AstraZeneca and the Fusion circular; Novartis and its offer to purchase; Sanofi and Vigil's merger 8-K and proxy supplement; and the Lilly and Verve release and Lilly's offer to purchase. Probabilities use the all-indication transition rates of 52.0%, 28.9%, 57.8% and 90.6% (Phase I to II, II to III, III to filing, filing to approval) from BIO, Informa and QLS. A completed Phase 1 is treated as entry to Phase II, Fusion's trigger as reaching a filing, and Vigil's first sale as approval.

Each column is computed the same way:

1. Fusion: $3.00 x 0.167042 = $0.501126. $21.00 + $0.501126 = $21.501126. $21.501126 / $10.64 = 2.020783, a 102.08% premium. Cash only: $21.00 / $10.64 = 1.973684, or 97.37%.
2. Regulus: $7.00 x 0.151340 = $1.059380. $7.00 + $1.059380 = $8.059380. $8.059380 / $3.37 = 2.391507, a 139.15% premium. Cash only: $7.00 / $3.37 = 2.077151, or 107.72%.
3. Vigil: $2.00 x 0.151340 = $0.302680. $8.00 + $0.302680 = $8.302680. $8.302680 / $2.48 = 3.347855, a 234.79% premium. Cash only: $8.00 / $2.48 = 3.225806, or 222.58%.
4. Verve: $3.00 x 0.150280 = $0.450840. $10.50 + $0.450840 = $10.950840. $10.950840 / $6.27 = 1.746545, a 74.65% premium. Cash only: $10.50 / $6.27 = 1.674641, or 67.46%.
5. Medians of four: cash only, (97.37% + 107.72%) / 2 = 102.545%; risk-adjusted, (102.08% + 139.15%) / 2 = 120.615%; every milestone paid, (125.56% + 303.23%) / 2 = 214.395%.

The cash-only figures reconcile to the acquirers' own statements: AstraZeneca reported a 97% premium to the March 18, 2024 close of $10.64, and Regulus reported a 108% premium to its April 29, 2025 close. Lilly stated its premium as about 113% to a 30-day volume-weighted average price, which is why the table rebases Verve to its last unaffected close. Sanofi stated no premium.

04Contingent Consideration and Stage

Headline figures overstate what was paid. Regulus, whose CVR equals its cash price, shows it most clearly: the all-milestones premium of 315.43% is more than twice the risk-adjusted 139.15%. The trigger matters as much as the face amount. Verve's CVR pays on the first U.S. Phase 3 dose, an event two transitions away, while Regulus pays only on FDA approval, three transitions away. A patent-related offset of up to $0.50 can also cut the Verve payment to $2.50 even if the milestone is met. Read as a multiple on invested capital for a holder who bought at the unaffected price, the risk-adjusted Regulus premium of 139.15% is about 2.39 times.

Disease area moves the result: BIO's cardiovascular rates give Verve 0.500 x 0.210 = 0.105000, or $0.3150 expected; oncology rates give Fusion 0.246 x 0.477 = 0.117342, or $0.3520; neurology rates give Vigil 0.268 x 0.531 x 0.867 = 0.123381, or $0.2468; and the report's "Other" category, which holds renal disease, gives Regulus 0.386 x 0.600 x 0.884 = 0.204734, or $1.4331. No CVR is discounted for the years to its milestone. Discounting would lower each value further, and the rate chosen is a judgment to state with the result.

05Control and the Unit of Account

Every premium in the table is a price for control. ASC 820 requires inputs consistent with the characteristics of the asset that market participants would consider, recognizes that those can call for a premium or discount (its examples are a control premium and a noncontrolling interest discount), and prohibits any premium or discount inconsistent with the unit of account (ASC 820-10-35-36B).

Deloitte reads this to bar control premiums as adjustments to Level 1 measurements while allowing that one may be appropriate at Level 2 or Level 3 after evaluating the relevant factors. A minority growth equity position carries no control, so an acquisition premium belongs in the sale scenario of a probability-weighted analysis, not in a direct uplift today.

The AICPA Accounting and Valuation Guide, Valuation of Portfolio Company Investments of Venture Capital and Private Equity Funds and Other Investment Companies, sets the practice frame. It is nonauthoritative guidance for investments held by entities within the scope of ASC 946, addressing unit of account, calibration and the impact of control and marketability (AICPA & CIMA). Its paragraph 10.02 defines calibration as using observed transactions in the portfolio company's own instruments, especially the fund's entry transaction, so later valuations begin from consistent assumptions (Plante Moran, 2019). ASC 820-10-35-24C imposes the same discipline. Precedent transactions supplement calibration, never replace it.

Two comparables need explicit treatment. Vigil's 222.58% cash premium exceeded the 80% to 200% range its own financial advisor applied to the $2.48 close, and Sanofi had made a $40 million strategic investment in Vigil in June 2024 that carried a right of first negotiation on the program. Vigil is a weaker indicator of an arm's-length premium; Fusion, at 527 days, is the stalest. Without Vigil, the risk-adjusted range narrows to 74.65% to 139.15%, with a median of 102.08%. Giving Vigil and Fusion lower weight is a professional judgment, not a sourced fact.

06Frequently asked questions

What is a precedent transactions analysis for a clinical-stage biotech?

It values a company by reference to prices acquirers paid for comparable companies. Without earnings, the usable measures are consideration per share and the premium to the unaffected share price, each restated for stage, modality, indication, contingent consideration, control and time. Under ASC 820 it is a market approach, and for a private company it is a Level 3 measurement.

Why probability-weight a contingent value right instead of using the headline value?

A headline "up to" value assumes every milestone is paid. Weighting each CVR by the probability of its own trigger, such as Phase 3 dosing or FDA approval, restates the price on the basis the acquirer actually bore. In the four deals examined, the median premium falls from 214.4% with every milestone paid to 120.6% on a risk-adjusted basis.

Can a minority investor apply an acquisition premium under ASC 820?

Not directly. ASC 820-10-35-36B prohibits a premium or discount inconsistent with the unit of account, and a minority position does not carry control. An acquisition premium is better used inside a scenario analysis, informing value in a sale scenario that is weighted by its likelihood and discounted to the measurement date.

Nothing in this piece is investment, legal, tax or accounting advice, and nothing in it is an offer to sell or a solicitation of an offer to buy any security.